TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells

Biochemical and Biophysical Research Communications

Volumn 463, Issue 4, 2015, Pages 638-643

  Tian, Tian ^a   Li, Aimin ^a   Lu, Hong ^a   Luo, Ran ^b   Zhang, Mingzhi ^a   Li, Zhaoming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Apoptosis; Glioma; TAZ; Temozolomide resistance

Indexed keywords

PDZ PROTEIN; PROTEIN MCL 1; TEMOZOLOMIDE; TRANSCRIPTIONAL COACTIVATOR WITH PDZ BINDING MOTIF; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; MCL1 PROTEIN, HUMAN; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; GENE OVEREXPRESSION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROGNOSIS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84936890041     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.05.115     Document Type: Article

References (23)

1. M.M. Mrugala Advances and challenges in the treatment of glioblastoma: a clinician's perspective Discov. Med. 15 2013 221 230
2. D.A. Reardon, and P.Y. Wen Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents Oncologist 11 2006 152 164
3. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek, C. Marosi, C.J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J.G. Cairncross, R.O. Mirimanoff E.O.f.R.a.T.o.C.B.T.a.R.O. Groups, N.C.I.o.C.C.T. Group Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
4. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, R.O. Mirimanoff E.O.f.R.a.T.o.C.B.T.a.R. Groups, N.C.I.o.C.C.T. Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996
5. K. Messaoudi, A. Clavreul, and F. Lagarce Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide Drug Discov. Today 2015 Mar 2 pii: S1359-6446(15)00080-X. http://dx.doi.org/10.1016/j.drudis.2015.02.011. [Epub ahead of print]
6. A. Errico Targeted therapies: hippo effector YAP1 inhibition-towards a new therapeutic option to overcome drug resistance Nat. Rev. Clin. Oncol. 12 2015 190
7. M. Santucci, T. Vignudelli, S. Ferrari, M. Mor, L. Scalvini, M.L. Bolognesi, E. Uliassi, and M.P. Costi The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment J. Med. Chem. 2015 Mar 11 [Epub ahead of print]
8. S. Piccolo, S. Dupont, and M. Cordenonsi The biology of YAP/TAZ: hippo signaling and beyond Physiol. Rev. 94 2014 1287 1312
9. M. Kodaka, and Y. Hata The mammalian Hippo pathway: regulation and function of YAP1 and TAZ Cell. Mol. Life Sci. 72 2015 285 306
10. X. Varelas The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease Development 141 2014 1614 1626
11. P.D. Li, X.J. Wang, Q. Shan, Y.H. Wu, and Z. Wang Evaluation of TAZ expression and its effect on tumor invasion and metastasis in human glioma Asian Pac. J. Trop. Med. 7 2014 757 760
12. J. Yuan, G. Xiao, G. Peng, D. Liu, Z. Wang, Y. Liao, Q. Liu, M. Wu, and X. Yuan MiRNA-125a-5p inhibits glioblastoma cell proliferation and promotes cell differentiation by targeting TAZ Biochem. Biophys. Res. Commun. 457 2015 171 176
13. K.P. Bhat, K.L. Salazar, V. Balasubramaniyan, K. Wani, L. Heathcock, F. Hollingsworth, J.D. James, J. Gumin, K.L. Diefes, S.H. Kim, A. Turski, Y. Azodi, Y. Yang, T. Doucette, H. Colman, E.P. Sulman, F.F. Lang, G. Rao, S. Copray, B.D. Vaillant, and K.D. Aldape The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma Genes Dev. 25 2011 2594 2609
14. Z. Li, T. Tian, X. Hu, X. Zhang, L. Li, F. Nan, Y. Chang, X. Wang, Z. Sun, F. Lv, and M. Zhang Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion Int. J. Clin. Exp. Pathol. 7 2014 631 639
15. Z. Li, T. Tian, X. Hu, X. Zhang, F. Nan, Y. Chang, F. Lv, and M. Zhang Six1 mediates resistance to paclitaxel in breast cancer cells Biochem. Biophys. Res. Commun. 441 2013 538 543
16. C.G.A.R. Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
17. T.C. Johannessen, and R. Bjerkvig Molecular mechanisms of temozolomide resistance in glioblastoma multiforme Expert Rev. Anticancer Ther. 12 2012 635 642
18. J.R. Silber, M.S. Bobola, A. Blank, and M.C. Chamberlain O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems Biochim. Biophys. Acta 1826 2012 71 82
19. M. Kim, T. Kim, R.L. Johnson, and D.S. Lim Transcriptional Co-repressor Function of the Hippo Pathway Transducers YAP and TAZ Cell Rep. 11 2015 270 282
20. Z. Li, Y. Wang, Y. Zhu, C. Yuan, D. Wang, W. Zhang, B. Qi, J. Qiu, X. Song, J. Ye, H. Wu, H. Jiang, L. Liu, Y. Zhang, L.N. Song, J. Yang, and J. Cheng The hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer Mol. Oncol. 9 2015 1091 1105
21. M. Bartucci, R. Dattilo, C. Moriconi, A. Pagliuca, M. Mottolese, G. Federici, A.D. Benedetto, M. Todaro, G. Stassi, F. Sperati, M.I. Amabile, E. Pilozzi, M. Patrizii, M. Biffoni, M. Maugeri-Saccà, S. Piccolo, and R. De Maria TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells Oncogene 34 2015 681 690
22. C. Gratas, Q. Séry, M. Rabé, L. Oliver, and F.M. Vallette Bak and Mcl-1 are essential for temozolomide induced cell death in human glioma Oncotarget 5 2014 2428 2435
23. R.Y. Li, L.C. Chen, H.Y. Zhang, W.Z. Du, Y. Feng, H.B. Wang, J.Q. Wen, X. Liu, X.F. Li, Y. Sun, D.B. Yang, T. Jiang, Y.L. Li, and C.L. Jiang MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma CNS Neurosci. Ther. 19 2013 477 483